Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children. The post Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma…
If leading hospitals are using these AI tools, and the companies mention HIPAA compliance on their websites, are the consumer AI health tools also regulated by HIPAA? Do consumers share a similar relationship with these companies as healthcare organizations do? The post Privacy Expectations in Consumer AI Tools: How Patient Use of ChatGPT Health and…
Today’s challenges — such as rapid technological innovations, shifting patient demographics, and mounting financial pressures — call not for just any leader but for a particular type of leader. They must be able to assess like clinicians and lead like CEOs. The post The Healthcare Industry Requires a New Kind of Leader appeared first on…
[Sponsored] Executives from Sellers Dorsey and eFax®by Consensus join MedCity News and share their insights impacting the healthcare industry. The post Future of Health Tech: From Structured Data to Scalable AI [Video] appeared first on MedCity News.
Eli Lilly’s new Lilly Employer Connect platform offers employers more flexible access to obesity drugs like Zepbound, but experts say it represents only incremental progress. The post Lilly Employer Connect Adds Flexibility for Employers But Isn’t Revolutionary, Expert Says appeared first on MedCity News.
Healthcare AI startups are experimenting with pricing models that tie their costs to real-world results, such as completed tasks or improved patient outcomes. While investors see this as a way to prove value, many hospitals remain skeptical, preferring predictable pricing. The post AI Startups Are Tying Fees to Completed Tasks. Will Hospitals Buy In? appeared…
The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder. The post Startup Atavistik Adds $40M for Clinical Trial in Rare Bleeding Disorder With No Approved Therapies appeared first on MedCity News.
[Sponsored] Healthcare executives spoke with MedCity News on how their businesses are using tech to shape the clinician and patient experience. The post How to Build Effective Referral Networks and Improve Patient Navigation [Video] appeared first on MedCity News.
This content is password-protected. To view it, please enter the password below. Password: The post Protected: Myth vs. Fact: The Operational Realities Shaping Sterile Processing Performance appeared first on Crothall Healthcare.
The move toward infusion centers as the preferred site of care is not a short-term response. It aligns with broader industry trends, including specialty drug pipelines that continue to favor infused biologics and a sustained rise in infusion demand. The post Why Hospital Outpatient Isn’t the Default for Long-Term Infusion Anymore appeared first on MedCity…